Quarterly ResultMay 11, 2026, 04:03 PM
ArriVent expects firmonertinib Phase 3 data mid-2026; ARR-002 advances
AI Summary
ArriVent BioPharma reported Q1 2026 financial results and provided significant pipeline updates. The company anticipates topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC by mid-2026. Additionally, its dual-targeting ADC, ARR-002, received IND clearance and is slated to dose its first patient in 2H 2026 for ovarian and endometrial cancers. ArriVent also highlighted the NMPA accelerated approval for firmonertinib in China and a strong cash position of $326.4 million, expected to fund operations into Q4 2027.
Key Highlights
- Topline firmonertinib Phase 3 data for EGFR exon 20 insertion mutant NSCLC expected mid-2026.
- ARR-002, a dual-targeting ADC, received IND clearance and plans to dose first patient in 2H 2026.
- Cash and investments totaled $326.4 million as of March 31, 2026.
- Cash runway is expected to fund operations into 4Q 2027.
- Firmonertinib received NMPA accelerated approval in China in February 2026 for second-line EGFR exon 20 insertion mutations.
- Net loss for Q1 2026 was $43.3 million, compared to $64.4 million in Q1 2025.
- Research and development expenses were $37.6 million for Q1 2026.
- ARR-217, a CDH17 targeted ADC, dosed its first patient in March 2026.